10-Q: BioLargo Reports 27% Revenue Increase in Q1 2024 Driven by Pet Odor Product Sales

BioLargo's Q1 2024 revenue increased by 27% year-over-year, primarily driven by sales of its private-label pet odor control product, while the company continues to develop its environmental and medical technologies.

Summary

• BioLargo, Inc. reported a 27% increase in revenue for the first quarter of 2024, reaching $4.76 million, compared to $3.742 million in the same period last year.
• The revenue growth was primarily due to a 29% increase in product revenue, driven by sales of the Pooph-branded pet odor control product, which accounted for 88% of the company's total revenue.
• Service revenue decreased slightly by 5% to $185,000.
• The company's net loss for the quarter was $775,000, or $0.003 per share, compared to a net loss of $494,000, or $0.001 per share, in Q1 2023.
• BioLargo generated $481,000 in net cash from operating activities during the quarter.
• The company continues to invest in research and development, particularly in its battery technology and PFAS removal system, with R&D expenses totaling $784,000 for the quarter.
• BioLargo sold $260,000 of its common stock to Lincoln Park Capital Fund, $228,000 of common stock and warrants to accredited investors, $475,000 of Clyra Medical common stock, and $50,000 of BETI common stock during the quarter.
• The company acknowledges substantial doubt about its ability to continue as a going concern without further revenue growth, cash generation, or financing activities.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there is strong revenue growth driven by a single product, the company is still operating at a loss, has a material weakness in internal controls, and has a going concern warning. The company is also reliant on external funding and has a number of subsidiaries that are not yet generating revenue. The company is making progress in its technology development, but the financial risks are significant.

Positives

• BioLargo achieved a significant 27% increase in overall revenue, demonstrating strong sales growth.
• The company generated positive net cash from operating activities of $481,000.
• The success of the Pooph-branded product highlights the potential of BioLargo's technology in consumer markets.
• BioLargo is actively developing and commercializing innovative technologies in environmental and medical fields, including PFAS removal and battery technology.
• The company has secured channel partner agreements for its PFAS treatment technology, expanding its market reach.
• BioLargo has added experienced veterans to the board of its water treatment subsidiary, BEST, to help with commercialization efforts.

Negatives

• The company reported a net loss of $775,000 for the quarter, indicating ongoing financial challenges.
• BioLargo is highly reliant on a single product, the Pooph-branded pet odor control product, for the majority of its revenue.
• The company's engineering subsidiary, BLEST, experienced a decrease in third-party revenue, focusing on internal projects.
• Clyra Medical and BETI are not yet generating revenue and are incurring losses.
• The company acknowledges substantial doubt about its ability to continue as a going concern without further revenue growth or financing.

Risks

• BioLargo's reliance on a single product for the majority of its revenue creates a significant risk if that product's sales decline.
• The company's ability to continue as a going concern is uncertain without further revenue growth, cash generation, or financing activities.
• The commercialization of new technologies, such as the AEC and battery technology, is subject to market acceptance and regulatory approvals.
• The company's internal control over financial reporting has a material weakness, which could lead to errors in financial reporting.
• The company faces competition in the environmental and medical technology markets.
• The company's subsidiaries, Clyra Medical and BETI, are not yet generating revenue and are incurring losses, which could impact the company's overall financial performance.
• The company's engineering subsidiary, BLEST, is experiencing a decrease in third-party revenue, which could impact its financial performance.

Future Outlook

BioLargo anticipates continued reliance on third parties for revenue generation and expects to need further investment capital to fund its business plans and new technologies. The company is focused on commercializing its PFAS treatment technology and battery technology, and is exploring joint ventures for its battery technology. The company expects Clyra's losses to continue in the near future as it works to finalize agreements with third parties to distribute its products.

Management Comments

• Every member of our team including PhD scientists, engineers, and entrepreneurs has a passion for seeking new, never-before-seen innovations that can make life better around the world.
• We care about safeguarding the environment and human health for future generations.
• We care about making technologies that are affordable and flexible enough to be accessed around the world.
• We care about being the best at what we do creating best-in-class technologies to solve big, tough cleantech challenges.

Industry Context

The report highlights BioLargo's focus on addressing critical environmental issues such as PFAS contamination and water pollution, which are significant concerns in the cleantech industry. The company's development of innovative solutions like the AEC and AOS aligns with the growing demand for sustainable and efficient water treatment technologies. The company's battery technology also addresses the need for improved energy storage solutions in the renewable energy sector. The company's medical device subsidiary, Clyra, is also addressing a need for improved surgical wound irrigation solutions.

Comparison to Industry Standards

• BioLargo's revenue growth of 27% is a positive sign, but its reliance on a single product for the majority of its revenue is a risk compared to diversified companies in the environmental technology sector.
• The company's net loss of $775,000 is not uncommon for early-stage technology companies, but it highlights the need for improved financial performance compared to established players.
• BioLargo's focus on PFAS removal with its AEC technology is timely, given the increasing regulatory scrutiny and market demand for such solutions, and the company's technology has been shown to meet new EPA standards.
• The company's battery technology is targeting a market with high growth potential, but it faces competition from established lithium-ion battery manufacturers and other emerging technologies.
• The company's engineering subsidiary, BLEST, is experiencing a decrease in third-party revenue, which is a concern compared to other engineering firms that have a more diversified client base.
• The company's medical device subsidiary, Clyra, is still in the early stages of commercialization, and its lack of revenue is not unusual for companies in this stage, but it needs to secure distribution partnerships to accelerate growth.

Stakeholder Impact

• Shareholders face the risk of further dilution due to the company's need for additional capital.
• Employees may be impacted by the company's financial challenges and potential restructuring.
• Customers may benefit from the company's innovative technologies, but may also be concerned about the company's financial stability.
• Suppliers may face risks related to the company's ability to pay its obligations.
• Creditors may be concerned about the company's ability to repay its debts.

Next Steps

• BioLargo will continue to focus on commercializing its PFAS treatment technology and battery technology.
• The company will explore joint ventures for its battery technology.
• Clyra Medical will work to finalize agreements with third parties to distribute its products.
• BioLargo will continue to seek additional funding through the sale of securities.
• The company will work to address the material weakness in its internal controls.

Key Dates

Keywords

BioLargo, PFAS, water treatment, odor control, battery technology, Clyra Medical, environmental technology, AEC, Pooph, BLEST, BETI, BEST, AROS, AOS, CupriDyne Clean